Table 3.
The likelihood to undergo surgical resection in the subgroup of patients with early-stage non-small-cell lung cancer, to receive radiotheraphy (stage III disease) or chemotherapy (advanced disease or small-cell lung cancer) estimated by crude and adjusted logistic regression models with ORs and 95% CI
| Surgical resection in early-stage NSCLC (N=1828) |
Radiotherapy in stage III disease (N=2771) |
Chemotherapy in advanced or SCLC (N=10 039) |
|||||||||||||
| N (%) | Crude |
Adjusted |
N (%) | Crude |
Adjusted |
N (%) | Crude |
Adjusted |
|||||||
| OR | 95 %CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | ||||
| Eligible patients | 899 (49.2) | – | – | – | – | 1054 (38.0) | – | – | – | – | 3661 (36.5) | – | – | – | – |
| Socioeconomic quintile | |||||||||||||||
| Q1 (affluent) | 126 (55.8) | 1.00 | Reference | 1.00 | Reference | 146 (36.2) | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | |
| Q2 | 156 (48.0) | 0.73 | 0.52 to 1.03 | 0.74 | 0.51 to 1.06 | 179 (39.3) | 1.14 | 0.87 to 1.51 | 1.16 | 0.88 to 1.54 | 555 (40.4) | 0.87 | 0.75 to 1.01 | 0.90 | 0.77 to 1.06 |
| Q3 | 171 (48.7) | 0.75 | 0.54 to 1.05 | 0.71 | 0.49 to 1.02 | 215 (39.1) | 1.13 | 0.87 to 1.47 | 1.17 | 0.90 to 1.53 | 591 (37.0) | 0.78 | 0.68 to 0.90 | 0.78 | 0.67 to 0.91 |
| Q4 | 230 (49.5) | 0.78 | 0.56 to 1.07 | 0.73 | 0.52 to 1.03 | 263 (39.7) | 1.16 | 0.90 to 1.49 | 1.18 | 0.91 to 1.53 | 666 (34.5) | 0.83 | 0.72 to 0.95 | 0.77 | 0.66 to 0.89 |
| Q5 (deprived) | 216 (46.9) | 0.70 | 0.51 to 0.96 | 0.67 | 0.48 to 0.95 | 251 (35.9) | 0.98 | 0.76 to 1.27 | 0.99 | 0.77 to 1.29 | 869 (35.9) | 0.83 | 0.73 to 0.95 | 0.75 | 0.65 to 0.87 |
| Test for trend (χ2, p value) | 2.32 | 0.13 | 1.13 | 0.29 | 0.10 | 0.75 | 0.18 | 0.67 | 980 (36.0) | 5.30 | 0.02 | 15.9 | <0.01 | ||
| Sex | |||||||||||||||
| Male | 475 (47.9) | 1.00 | Reference | 1.00 | Reference | 632 (37.8) | 1.00 | Reference | 1.00 | Reference | 2195 (37.7) | 1.00 | Reference | 1.00 | Reference |
| Female | 424 (50.7) | 1.12 | 0.93 to 1.35 | 1.16 | 0.95 to 1.41 | 422 (38.3) | 1.02 | 0.87 to 1.19 | 1.02 | 0.87 to 1.20 | 1466 (34.8) | 0.88 | 0.81 to 0.96 | 0.90 | 0.82 to 0.98 |
| Test for trend (χ2, p value) | 2.28 | 0.13 | 2.63 | 0.11 | 0.07 | 0.80 | 0.85 | 0.36 | 8.76 | <0.01 | 4.84 | 0.03 | |||
| Age at diagnosis | |||||||||||||||
| 0–59 | 203 (71.7) | 1.00 | Reference | 1.00 | Reference | 197 (45.4) | 1.00 | Reference | 1.00 | Reference | 1089 (60.4) | 1.00 | Reference | 1.00 | Reference |
| 60–69 | 320 (61.3) | 0.62 | 0.46 to 0.85 | 0.65 | 0.48 to 0.89 | 303 (39.5) | 0.79 | 0.62 to 1.00 | 0.81 | 0.64 to 1.03 | 1357 (49.1) | 0.63 | 0.56 to 0.71 | 0.66 | 0.58 to 0.75 |
| 70–79 | 318 (47.8) | 0.36 | 0.27 to 0.49 | 0.38 | 0.28 to 0.52 | 362 (38.2) | 0.74 | 0.59 to 0.94 | 0.79 | 0.62 to 1.00 | 1020 (30.9) | 0.29 | 0.26 to 0.33 | 0.32 | 0.28 to 0.36 |
| 80+ | 58 (16.3) | 0.08 | 0.05 to 0.11 | 0.08 | 0.05 to 0.12 | 192 (30.8) | 0.54 | 0.42 to 0.69 | 0.56 | 0.43 to 0.73 | 195 (9.0) | 0.06 | 0.05 to 0.08 | 0.07 | 0.06 to 0.08 |
| Test for trend (χ2, p value) | 39.0 | <0.01 | 31.1 | <0.01 | 17.2 | <0.01 | 9.01 | <0.01 | 869.4 | <0.01 | 677.2 | <0.01 | |||
| Charlson Score | |||||||||||||||
| 0 | 398 (58.4) | 1.00 | Reference | 1.00 | Reference | 466 (41.5) | 1.00 | Reference | 1.00 | Reference | 1960 (45.1) | 1.00 | Reference | 1.00 | Reference |
| 1 | 257 (52.8) | 0.82 | 0.65 to 1.03 | 0.87 | 0.68 to 1.12 | 288 (39.0) | 0.90 | 0.75 to 1.09 | 0.93 | 0.76 to 1.12 | 943 (37.0) | 0.72 | 0.65 to 0.79 | 0.82 | 0.74 to 0.92 |
| 2+ | 215 (44.8) | 0.60 | 0.48 to 0.76 | 0.78 | 0.60 to 1.01 | 216 (32.7) | 0.70 | 0.57 to 0.85 | 0.75 | 0.61 to 0.92 | 616 (26.9) | 0.46 | 0.41 to 0.51 | 0.61 | 0.54 to 0.68 |
| Test for trend (χ2, p value) | 5.12 | <0.01 | 1.57 | 0.21 | 12.9 | <0.01 | 8.20 | <0.01 | 217.1 | <0.01 | 74.3 | <0.01 | |||